Montara Therapeutics is a preclinical-stage biopharmaceutical company pursuing novel approaches to develop safer and more efficacious treatments for neurological diseases. Montara’s BrainOnly platform allows brain-specific pharmacology utilizing existing and novel chemical warheads, restricting deleterious on-target off-tissue peripheral activity. BrainOnly holds the potential to drug numerous targets previously considered undruggable. The company is backed by top-tier investors, including Two Bear Capital, SV Health Investors’ Dementia Discovery Fund, KdT Ventures, and Dolby Family Ventures. For more information, visit montaratx.com.
.jpg)
